Cellectis (NASDAQ:CLLS) & Capricor Therapeutics (NASDAQ:CAPR) Head to Head Analysis

Cellectis (NASDAQ:CLLS – Get Free Report) and Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility & Risk

Cellectis has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Insider & Institutional Ownership

63.9% of Cellectis shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cellectis and Capricor Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectis -396.85% -319.93% -46.54%
Capricor Therapeutics N/A -56.71% -42.71%

Analyst Recommendations

This is a summary of recent ratings and price targets for Cellectis and Capricor Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis 2 2 2 1 2.29
Capricor Therapeutics 1 5 5 0 2.36

Cellectis presently has a consensus price target of $5.46, indicating a potential upside of 495.42%. Capricor Therapeutics has a consensus price target of $30.09, indicating a potential upside of 297.61%. Given Cellectis’ higher probable upside, equities research analysts plainly believe Cellectis is more favorable than Capricor Therapeutics.

Earnings and Valuation

This table compares Cellectis and Capricor Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellectis $79.59 million 1.16 -$67.59 million ($1.27) -0.72
Capricor Therapeutics $22.27 million 19.76 -$105.04 million ($2.64) -2.87

Cellectis has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Summary

Cellectis beats Capricor Therapeutics on 9 of the 15 factors compared between the two stocks.

About Cellectis

(Get Free Report)

Cellectis is a biotechnology company focused on developing gene-edited cell and gene therapies, with an emphasis on treatments for cancer. Founded in France in 1999, the company operates in France and the United States. Its research centers on TALEN gene-editing technology, which it uses to modify cells for potential therapeutic applications. Cellectis is developing allogeneic CAR T-cell therapies made from donor T cells, an approach intended to create treatments that can be prepared for use by multiple patients rather than made individually for each patient.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.